Active Ingredient History
Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980. It was developed at Biogen, and ultimately marketed by Schering-Plough under the trade name Intron-A. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon Alfa R. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 3)
Acute-On-Chronic Liver Failure (Phase 4)
Adenocarcinoma (Phase 2)
Adenoma, Islet Cell (Phase 2)
Adrenal Cortex (Phase 2)
Alcoholism (Phase 4)
Anemia (Phase 4)
Antiviral Agents (Phase 4)
Anus Neoplasms (Phase 1)
Asian Americans (Phase 4)
Astrocytoma (Phase 3)
Behcet Syndrome (Phase 2)
Bile Duct Neoplasms (Phase 2)
Blast Crisis (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Burns (Phase 3)
Carcinoid Tumor (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Basal Cell (Phase 4)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma in Situ (Phase 2/Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2/Phase 3)
Cholangiocarcinoma (Phase 2)
Chronic Disease (Phase 4)
Chronic Pain (Phase 2)
Cicatrix, Hypertrophic (Phase 3)
Coinfection (Phase 3)
Colonic Neoplasms (Phase 3)
Colorectal Neoplasms (Phase 3)
Conjunctival Neoplasms (Phase 4)
Corneal Diseases (Phase 4)
Cough (Phase 2)
COVID-19 (Phase 4)
Craniopharyngioma (Phase 2)
Depression (Phase 3)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetes Mellitus, Type 2 (Phase 4)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Drugs, Investigational (Phase 3)
Endoscopy (Phase 2/Phase 3)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fatty Liver (Phase 4)
Fibrosis (Phase 4)
Gastrointestinal Stromal Tumors (Phase 2)
Genotype (Phase 4)
Gestational Trophoblastic Disease (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 2)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 3)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 4)
Hemoglobinopathies (Phase 4)
Hemophilia A (Phase 4)
Hepacivirus (Phase 4)
Hepatic Insufficiency (Phase 1)
Hepatitis (Phase 4)
Hepatitis B (Phase 4)
Hepatitis B, Chronic (Phase 4)
Hepatitis B virus (Phase 2)
Hepatitis C (Phase 4)
Hepatitis, Chronic (Phase 4)
Hepatitis D (Phase 2)
Hepatitis D, Chronic (Phase 4)
Herpangina (Phase 4)
Herpesvirus 8, Human (Phase 2)
HIV (Phase 4)
HIV Infections (Phase 4)
HLA-A2 Antigen (Phase 2)
Human papillomavirus 16 (Phase 2/Phase 3)
Hypoxia (Phase 2)
Infections (Phase 3)
Influenza A virus (Phase 2)
Influenza, Human (Phase 1)
Insulin Resistance (Phase 4)
Interferon-alpha (Phase 3)
Intestinal Neoplasms (Phase 3)
Kidney (Phase 1/Phase 2)
Kidney Failure, Chronic (Phase 4)
Kidney Neoplasms (Phase 3)
Kidney Transplantation (Phase 4)
Leukemia (Phase 3)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Ligaments (Phase 1/Phase 2)
Liver (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Cirrhosis, Experimental (Phase 2/Phase 3)
Liver Diseases (Phase 4)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 4)
Lung Diseases (Phase 2)
Lung Diseases, Interstitial (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 4)
Lymphomatoid Granulomatosis (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Mastocytosis, Systemic (Phase 2/Phase 3)
Melanoma ()
Menopause (Phase 3)
Mesothelioma (Phase 1/Phase 2)
Mesothelioma, Malignant (Phase 3)
Multiple Myeloma (Phase 3)
Multiple Sclerosis (Phase 2)
Mycosis Fungoides (Phase 4)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 4)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatosis 1 (Phase 2)
Opioid-Related Disorders (Phase 3)
Osteosarcoma (Phase 3)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Papilloma (Phase 2)
Papillomavirus Infections (Phase 2/Phase 3)
Penile Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 1/Phase 2)
Pharmacokinetics (Phase 2)
Philadelphia Chromosome (Phase 2)
Polycythemia Vera (Phase 3)
Polymorphism, Genetic (Phase 4)
Precancerous Conditions (Phase 2)
Primary Myelofibrosis (Phase 3)
Prostatic Neoplasms (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Pulmonary Fibrosis (Phase 2)
Rectal Neoplasms (Phase 3)
Recurrence (Phase 4)
Renal Dialysis (Phase 4)
Renal Insufficiency (Phase 1)
Renal Replacement Therapy (Phase 4)
Respiratory Tract Diseases (Phase 2)
Respiratory Tract Infections (Phase 2)
Rhinovirus (Phase 2)
Risk Factors (Phase 3)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Kaposi (Phase 2)
Self Efficacy (Phase 2/Phase 3)
Skin Neoplasms (Phase 3)
Small Cell Lung Carcinoma (Phase 2)
Stomach Neoplasms (Phase 3)
Substance-Related Disorders (Phase 4)
Sustained Virologic Response (Phase 4)
Testicular Neoplasms (Phase 2)
Thalassemia (Phase 4)
Therapeutics (Phase 4)
Therapeutic Uses (Phase 4)
Thrombocythemia, Essential (Phase 3)
Thrombocytopenia (Phase 4)
Thymoma (Phase 2)
Treatment Failure (Phase 2)
Ulcer (Phase 2)
Urethral Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 2)
Vascular Grafting (Phase 2)
Virus Diseases (Phase 4)
Wilms Tumor (Phase 2)
Zollinger-Ellison Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
